Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 767551 (COR-101) for Post-exposure Prevention of COVID-19
NCT04894474Phase 3Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2021
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of COR-101 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Symptomatic SARS-CoV-2 infection at 31 days. Planned start Jun 2021; status: withdrawn.
02
Drugs
COR-101
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04894474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04894474.